CL2019003309A1 - Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. - Google Patents
Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.Info
- Publication number
- CL2019003309A1 CL2019003309A1 CL2019003309A CL2019003309A CL2019003309A1 CL 2019003309 A1 CL2019003309 A1 CL 2019003309A1 CL 2019003309 A CL2019003309 A CL 2019003309A CL 2019003309 A CL2019003309 A CL 2019003309A CL 2019003309 A1 CL2019003309 A1 CL 2019003309A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- dengue virus
- refers
- virus replication
- replication inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE INDOLINA SUSTITUIDOS, A MÉTODOS PARA PREVENIR O TRATAR INFECCIONES VIRALES POR DENGUE MEDIANTE EL USO DE DICHOS COMPUESTOS Y TAMBIÉN SE REFIERE A DICHOS COMPUESTOS PARA SU USO COMO MEDICAMENTO, MÁS PREFERENTEMENTE, PARA SU USO COMO MEDICAMENTO PARA TRATAR O PREVENIR INFECCIONES VIRALES POR DENGUE. LA PRESENTE INVENCIÓN SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS O PREPARADOS COMBINADOS DE LOS COMPUESTOS, A LAS COMPOSICIONES O PREPARADOS PARA SU USO COMO UN MEDICAMENTO, MÁS PREFERENTEMENTE PARA LA PREVENCIÓN O EL TRATAMIENTO DE INFECCIONES VIRALES POR DENGUE. LA INVENCIÓN TAMBIÉN SE REFIERE A PROCESOS PARA LA PREPARACIÓN DE LOS COMPUESTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17172247 | 2017-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019003309A1 true CL2019003309A1 (es) | 2020-03-20 |
Family
ID=58745159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019003309A CL2019003309A1 (es) | 2017-05-22 | 2019-11-18 | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. |
Country Status (29)
Country | Link |
---|---|
US (2) | US11053196B2 (es) |
EP (1) | EP3630724B1 (es) |
JP (1) | JP7179773B2 (es) |
KR (1) | KR102625991B1 (es) |
CN (1) | CN110753682B (es) |
AR (1) | AR111820A1 (es) |
AU (1) | AU2018274101C1 (es) |
BR (1) | BR112019024311A2 (es) |
CA (1) | CA3061026C (es) |
CL (1) | CL2019003309A1 (es) |
CO (1) | CO2019013042A2 (es) |
CR (1) | CR20190531A (es) |
DK (1) | DK3630724T3 (es) |
EA (1) | EA039702B1 (es) |
EC (1) | ECSP19083621A (es) |
ES (1) | ES2884157T3 (es) |
HR (1) | HRP20210724T1 (es) |
HU (1) | HUE054379T2 (es) |
IL (1) | IL270727B2 (es) |
LT (1) | LT3630724T (es) |
MX (1) | MX2019013878A (es) |
PE (1) | PE20200342A1 (es) |
PH (1) | PH12019502577A1 (es) |
SI (1) | SI3630724T1 (es) |
TW (1) | TWI771420B (es) |
UA (1) | UA125970C2 (es) |
UY (1) | UY37741A (es) |
WO (1) | WO2018215316A1 (es) |
ZA (1) | ZA201907713B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
MX2018011784A (es) | 2016-03-31 | 2019-02-13 | Janssen Pharmaceuticals Inc | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. |
BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
MA52976A (fr) * | 2018-06-19 | 2021-04-28 | Novartis Ag | Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations |
WO2020139991A1 (en) | 2018-12-27 | 2020-07-02 | Agios Pharmaceuticals, Inc. | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
WO2023278564A1 (en) | 2021-07-02 | 2023-01-05 | Mirati Therapeutics, Inc. | Aminopyridine-based mta-cooperative prmt5 inhibitors |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
CA2308443A1 (en) | 1997-10-27 | 1999-05-06 | Michael Lyle Denney | Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors |
GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
US6861504B2 (en) | 2001-05-03 | 2005-03-01 | Cbr, Inc. | Compounds and methods for the modulation of CD154 |
WO2003050295A2 (en) | 2001-12-12 | 2003-06-19 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating hsp90 binding activity |
GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
JP2008526980A (ja) | 2005-01-14 | 2008-07-24 | ジェネラブズ テクノロジーズ インコーポレーティッド | ウイルス感染症を治療するためのインドール誘導体 |
US20060194835A1 (en) | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
CA2726985A1 (en) | 2008-06-03 | 2009-12-10 | Siga Technologies, Inc. | Small molecule inhibitors for the treatment or prevention of dengue virus infection |
US8143259B2 (en) | 2008-08-19 | 2012-03-27 | Janssen Pharmaceutica, Nv | Cold menthol receptor antagonists |
CN102160233B (zh) | 2008-08-22 | 2013-12-04 | 日本化药株式会社 | 染料敏化的光电转换器件 |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
US7948798B1 (en) | 2009-07-22 | 2011-05-24 | Marvell International Ltd. | Mixed multi-level cell and single level cell storage device |
PT2523951E (pt) | 2010-01-15 | 2015-09-14 | Gilead Sciences Inc | Inibidores de vírus flaviviridae |
EP2552211A4 (en) | 2010-03-26 | 2013-10-23 | Glaxo Group Ltd | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER |
JP5716205B2 (ja) | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法 |
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
GB201305376D0 (en) * | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
JP6464176B2 (ja) | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 芳香族p2’基を有する第xia因子阻害剤としてのマクロ環 |
SG11201702463YA (en) | 2014-10-01 | 2017-04-27 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
NO2721243T3 (es) | 2014-10-01 | 2018-10-20 | ||
ME03344B (me) | 2014-10-01 | 2019-10-20 | Janssen Pharmaceuticals Inc | Mono- ili di-supstituisani indoli kao inнibitori replikacije denga virusa |
JOP20150335B1 (ar) * | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EP3370698B1 (en) | 2015-11-03 | 2022-01-26 | Zoetis Services LLC | Sol-gel polymer composites and uses thereof |
BR112018068538B1 (pt) | 2016-03-31 | 2023-12-12 | Takeda Pharmaceutical Company Limited | Composto, medicamento, e, uso de um composto |
WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
MX2018011784A (es) | 2016-03-31 | 2019-02-13 | Janssen Pharmaceuticals Inc | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. |
EA039392B1 (ru) | 2016-04-01 | 2022-01-21 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способ лечения рака с применением замещенного аминопуринового соединения |
BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
IL296966A (en) | 2016-04-01 | 2022-12-01 | Amgen Inc | Chimeric flt-3 receptors and methods of using them |
JOP20170069B1 (ar) * | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CN113150170A (zh) | 2016-04-01 | 2021-07-23 | 凯德药业股份有限公司 | 嵌合受体及其方法和用途 |
UA123912C2 (uk) | 2016-04-01 | 2021-06-23 | Басф Се | Біциклічні сполуки |
TW202313671A (zh) | 2016-04-01 | 2023-04-01 | 美商凱特製藥公司 | 嵌合抗原和t細胞受體及使用方法 |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
-
2018
- 2018-05-18 PE PE2019002416A patent/PE20200342A1/es unknown
- 2018-05-18 MX MX2019013878A patent/MX2019013878A/es unknown
- 2018-05-18 WO PCT/EP2018/063029 patent/WO2018215316A1/en active Application Filing
- 2018-05-18 TW TW107116922A patent/TWI771420B/zh not_active IP Right Cessation
- 2018-05-18 EA EA201992784A patent/EA039702B1/ru unknown
- 2018-05-18 HU HUE18729051A patent/HUE054379T2/hu unknown
- 2018-05-18 IL IL270727A patent/IL270727B2/en unknown
- 2018-05-18 EP EP18729051.5A patent/EP3630724B1/en active Active
- 2018-05-18 SI SI201830306T patent/SI3630724T1/sl unknown
- 2018-05-18 CA CA3061026A patent/CA3061026C/en active Active
- 2018-05-18 CN CN201880033731.2A patent/CN110753682B/zh active Active
- 2018-05-18 US US16/614,715 patent/US11053196B2/en active Active
- 2018-05-18 KR KR1020197037345A patent/KR102625991B1/ko active IP Right Grant
- 2018-05-18 UA UAA201912061A patent/UA125970C2/uk unknown
- 2018-05-18 ES ES18729051T patent/ES2884157T3/es active Active
- 2018-05-18 JP JP2019564452A patent/JP7179773B2/ja active Active
- 2018-05-18 LT LTEP18729051.5T patent/LT3630724T/lt unknown
- 2018-05-18 DK DK18729051.5T patent/DK3630724T3/da active
- 2018-05-18 CR CR20190531A patent/CR20190531A/es unknown
- 2018-05-18 AU AU2018274101A patent/AU2018274101C1/en active Active
- 2018-05-18 BR BR112019024311-9A patent/BR112019024311A2/pt active Search and Examination
- 2018-05-22 AR ARP180101352A patent/AR111820A1/es unknown
- 2018-05-22 UY UY0001037741A patent/UY37741A/es unknown
-
2019
- 2019-11-18 CL CL2019003309A patent/CL2019003309A1/es unknown
- 2019-11-18 PH PH12019502577A patent/PH12019502577A1/en unknown
- 2019-11-21 ZA ZA2019/07713A patent/ZA201907713B/en unknown
- 2019-11-22 EC ECSENADI201983621A patent/ECSP19083621A/es unknown
- 2019-11-22 CO CONC2019/0013042A patent/CO2019013042A2/es unknown
-
2021
- 2021-05-10 HR HRP20210724TT patent/HRP20210724T1/hr unknown
- 2021-05-28 US US17/334,432 patent/US11702387B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003309A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
CL2019002745A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
CL2019002744A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
CL2019003294A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
CL2018002718A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
CL2018002758A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue. | |
CL2018002784A1 (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
CL2018002729A1 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
UY36674A (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
CL2017000782A1 (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
UY36518A (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue |